Optimal use of intravenous landiolol in acute cardiac care

Editorial of the Special Issue Titled “Drug Candidates for the Prevention and Treatment of Cardiovascular Diseases”

“…Schnaubelt S et al studied landiolol, a highly β1-selective beta-blocker, in critically ill patients hospitalized in intensive care units (contribution 8). That drug has been recognized as a well-tolerated, safe and effective β-blocker, especially recommended in acute conditions [ 7 ]. In patients diagnosed with STEMI undergoing coronary angioplasty, the incubation of H9c2 cells with exosomes reperfused with citicoline favorably modified the expression of specific miRNAs and proteins related to cardioprotection (contribution 9).…”